Researchers observed an overall increase in the absolute median cost of the “best available” guideline-concordant treatments for common solid tumor malignancies from 2017 to 2021.

Lu]Lu-PSMA-617 radiopharmaceutical therapy has been approved for the treatment of men with metastatic castration-resistant ...